Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Unusual Whales
A new drug, TUDRIQEV™, has been granted accelerated approval by the FDA for use in combination with nivolumab. The drug is scheduled to be launched within the next 60 days. This approval opens up new treatment options for patients, particularly those with certain medical conditions.
